FDA Opens Public Comment on Ibogaine Clinical Trial Design

October 5, 2026

Photo by National Cancer Institute via Unsplash.

On Monday, October 5, 2026, the FDA published a Request for Information asking a question that's been looming over the psychedelic research world for years: if you're going to run early-stage clinical trials on ibogaine, how do you actually design them so they're safe? Ibogaine isn't a gentle compound. It's a psychoactive alkaloid derived from the root bark of the iboga shrub, it's been used informally to treat opioid withdrawal for decades, and it carries real cardiac risk that has shown up in case reports and fatalities tied to unsupervised use abroad. The FDA isn't asking whether ibogaine should be legal. It's asking how researchers, sponsors, and clinicians should structure the first rigorous trials so the agency isn't flying blind when applications start landing on its desk.

What the FDA Is Actually Asking

Photo by WikiImages via Pixabay.

The Request for Information, published in the Federal Register on October 5, is narrowly focused on trial architecture rather than policy. The FDA wants to hear from researchers, clinicians, patient advocates, and companies about what a defensible early-phase study of an ibogaine product should look like before anyone scales up to larger trials. That includes basic questions about general study design and which patient populations are appropriate candidates for first-in-human or early dose-finding work -- people with opioid use disorder, alcohol use disorder, PTSD, or some other indication entirely.

Dose selection gets particular attention. The agency is soliciting feedback on dose-ascending protocols that start small and move in careful increments, floating the idea of sequential dose-ascending cohorts with a starting dose that would not exceed 10 mg/kg -- a figure meant to anchor the conversation rather than lock in a final number. Safety monitoring is the other major thread, with the FDA specifically asking how sponsors should watch for cardiac and neurologic adverse events during and after dosing, given how ibogaine behaves in the body.

The RFI also touches on the ethical scaffolding around any of this: informed consent processes, oversight structures, and how trial sponsors should handle a substance with a complicated legal and cultural history. None of this is abstract housekeeping. It's the FDA trying to get ahead of applications it expects to receive. Comments are open for 45 days, through November 20, and anyone with relevant clinical, scientific, or regulatory experience can weigh in through the Federal Register docket.

Why the Agency Is Being Cautious

Photo by Dalila Dalprat via Pexels.

The caution here isn't bureaucratic reflex -- it's written directly into the notice. The Federal Register filing states plainly that research on ibogaine to date has significant limitations, and that there's real uncertainty about its benefit-risk profile. That's a notable admission for a substance that's been the subject of enthusiastic word-of-mouth treatment claims for opioid withdrawal since the 1960s but has almost no controlled, peer-reviewed trial data behind it in the United States.

Michael Davis, director of the FDA's Center for Drug Evaluation and Research, framed it as a balancing act: patients facing serious, treatment-resistant conditions deserve rigorous scientific investigation, but that investigation can't come at the expense of basic safety protections. The specific worry is cardiac. Ibogaine is associated with QT-interval prolongation, a disruption to the heart's electrical cycle that can trigger life-threatening ventricular arrhythmias -- and this risk shows up even at doses considered therapeutic, not just at the high recreational or ceremonial doses blamed for deaths at unregulated clinics abroad.

That concern was underscored at the FDA's September 14 public hearing, where a regulatory consultant warned the agency and attendees that there is currently no validated model for predicting which patients face the highest cardiac risk from ibogaine. In other words, researchers don't yet have a reliable way to screen out the people most likely to be harmed, which is precisely the kind of gap an RFI like this is meant to start closing.

It's worth noting what the FDA explicitly says it does not want comments on: legalization, decriminalization, ibogaine's Schedule I status, religious or ceremonial use, or the safety of any particular commercial product. This is a research-design conversation, not a policy referendum.

The Trump Executive Order Backdrop

Photo by Cristian Loayza via Pexels.

This RFI didn't appear out of nowhere. It traces back to Executive Order 14401, Accelerating Medical Treatments for Serious Mental Illness, which President Trump signed on April 18, 2026. The order directed the FDA and DEA to work together on building Right to Try access pathways specifically for ibogaine research, and it committed $50 million in federal funds designed to match state-level investment in ibogaine studies dollar for dollar.

It's important to be precise about what that order actually did and didn't do. It did not legalize any psychedelic substance. It did not reschedule anything. It did not approve a single drug for any use. Ibogaine remains a Schedule I controlled substance under federal law, meaning it's still classified as having no accepted medical use and a high potential for abuse -- at least on paper, even as the executive branch pushes money and infrastructure toward studying it.

According to Reuters reporting, federal officials are now moving to stand up the first government-funded clinical trials of ibogaine aimed at opioid addiction and PTSD, which would be a meaningful shift from the patchwork of privately funded, offshore, or underground treatment programs that have defined ibogaine use in the U.S. for decades. The October RFI reads like the regulatory plumbing being laid down ahead of that wave -- the FDA trying to make sure that when federally backed trials do launch, they're built on something sturdier than anecdote and overseas clinic data.

A Pipeline Already Taking Shape

Photo by Mikhail Nilov via Pexels.

The regulatory groundwork is catching up to a pipeline that's already moving. The FDA has cleared an Investigational New Drug application from DemeRx for DMX-1001, an oral formulation of noribogaine, ibogaine's primary active metabolite, targeting alcohol use disorder. That clearance marks the first FDA-authorized clinical study of an ibogaine derivative in the United States, and DemeRx is reportedly aiming for Phase 2 trials in 2027.

States aren't waiting on Washington either. Texas, Kentucky, Mississippi, and Colorado have all launched ibogaine research funds or state-backed programs during 2026, a remarkable run for a Schedule I substance that most state legislatures wouldn't have touched five years ago. Texas's commitment is the headline figure here -- reportedly growing toward $100 million, which would make it one of the largest state-level bets on psychedelic research anywhere in the country, dwarfing most psilocybin or MDMA research funding efforts to date.

Kentucky's SB77 and comparable measures in other statehouses point to something unusual: bipartisan interest in ibogaine research despite its federal scheduling status. Lawmakers in red states have largely framed this around opioid addiction treatment and veteran mental health, which has proven to be a politically durable combination even where broader psychedelic reform hasn't gained traction. The result is a strange but real dynamic -- state money and political will moving faster than federal law, with the FDA's RFI functioning as an attempt to make sure the science underneath all that momentum doesn't come up short.

What Happens Next

Photo by Ron Lach via Pexels.

For now, the path forward is straightforward on paper. Researchers, clinicians, advocacy organizations, and members of the public can submit comments through the Federal Register docket until the window closes on November 20. The FDA says it will use that input to shape future guidance for sponsors designing early-phase ibogaine trials -- the kind of document that tells a company or research institution what the agency expects to see before it even considers an IND application.

It's worth being clear-eyed about what this RFI is not. It does not change ibogaine's Schedule I status. It does not approve any treatment, product, or protocol. It's a data-gathering exercise, one piece of a much longer regulatory process that typically runs from preclinical data through multiple phases of human trials before anything resembling an approved drug reaches a pharmacy or clinic.

If you're in a state that's launched an ibogaine research fund or you've heard about a program nearby, don't assume that translates into legal access for you as a patient. State research funding and federal scheduling are two different legal tracks, and the gap between them has caught people off guard before with other substances. Confirm current state and federal law before assuming anything is legally available, and treat anything marketed outside a registered clinical trial with real skepticism given the cardiac risks regulators keep flagging.

What's happening with ibogaine right now is a regulatory agency trying to catch up to momentum it didn't fully generate. State legislatures have committed tens of millions of dollars, an executive order has put federal matching funds and Right to Try pathways on the table, and at least one derivative compound already has an active IND. None of that required the FDA to first decide how a safe, well-designed ibogaine trial should look -- and that's exactly the gap this RFI is trying to close before it becomes a problem.

The more interesting story here isn't really about ibogaine specifically. It's about what happens when state money and political enthusiasm for a treatment outpace the basic science needed to use it responsibly. The FDA seems to understand that dynamic doesn't resolve itself by waiting. Getting dose escalation limits, cardiac monitoring standards, and patient selection criteria settled now -- before trials multiply across four or five states with very different levels of oversight -- is the agency's best shot at keeping this research wave from producing the kind of preventable harm that's dogged ibogaine's reputation for years.